Clopixol-Acufaz solution for injection 50 mg/ml ampoule 1 ml No. 10

Clopixol-Acufaz injection solution is indicated for the initial treatment of acute psychoses, manic states and chronic psychoses in the exacerbation phase.

Composition

Active ingredient: zuclopenthixol;

1 ml of solution contains 50 mg of zuclopenthixol acetate;

Excipients: medium chain triglycerides.

Contraindication

Hypersensitivity to the components of the drug. Circulatory collapse, depression of consciousness of any origin (for example, as a result of alcohol, barbiturate or opioid intoxication), coma.

Method of application

Clopixol-Acufaz is administered as an injection into the upper outer quadrant of the buttock. Injections of more than 2 ml should be given in two injections into different sites. Local tolerance is good.

Application features

Pregnant women

It should not be administered during pregnancy unless the expected benefit to the patient outweighs the theoretical risk to the fetus.

Children

Use in children and adolescents is not recommended due to lack of clinical data.

Drivers

Patients should not drive if they experience blurred vision.

Overdose

Due to the dosage form, overdose is unlikely.

Symptoms: drowsiness, coma, extrapyramidal disorders, convulsions, hypotension, shock, hypo- or hyperthermia.

With simultaneous overdose with drugs that can affect cardiac activity, there have been cases of ECG changes, QT prolongation, torsades de pointes and ventricular arrhythmias, and cardiac arrest.

Treatment. Symptomatic and supportive. Measures should be taken to support the respiratory and cardiovascular systems. Adrenaline should not be used as this may lead to a further decrease in blood pressure. Convulsions can be treated with diazepam and movement symptoms with biperiden.

Side effects

Interaction

Zuclopenthixol decanoate may enhance the sedative effects of alcohol, barbiturates and central nervous system inhibitors.

Neuroleptics may enhance or reduce the effect of antihypertensive agents; the hypotensive effect of guanethidine and similarly acting agents is weakened.

Storage conditions

Store in the original packaging to protect from light, out of the reach of children at a temperature not exceeding 30 °C.

Shelf life - 2 years.